The value of inflammatory indexes in colorectal cancers


KARABACAK U., Derebey M., Tarım İ. A.

Medicine Science, cilt.12, sa.2, ss.453-457, 2023 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.5455/medscience.2023.03.043
  • Dergi Adı: Medicine Science
  • Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.453-457
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

In recent years, a relationship has been established between inflammatory indexes and the prognosis of many cancers. Although there are many studies investigating their relationship with colorectal cancers (CRC), there is a serious difference between the results in the related literature. The present study aimed to share our own experience with inflammatory indexes in CRC patients. Patients with a diagnosis of CRC who underwent surgery between January 2019 and June 2022 were retrospectively scanned. Exclusion criteria were as follows; being in a septic state before surgery, accompanying hematological disease, receiving neoadjuvant chemotherapy/radiotherapy, being diagnosed with recurrent CRC, undergoing emergency surgery, receiving immunosuppressive or anti-inflammatory treatment. Therefore, the study was conducted with 52 patients. Demographic information, tumor localization, stages and pathology data of the patients were examined. The relationship between these variables and the systemic immune-inflammation index (SII), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) was investigated. A significant correlation was found between pathological T stages and SII (p=0.008), NLR (p<0.001) and PLR (p=0.035). No correlation was found between inflammatory indexes and Age, Tumor Diameter, N Stage, Total Lymph Node Count, Metastatic Lymph Node Count. In our study, inflammatory indexes were found to be associated only with the T stage. Considering our results together with the variable results in the literature, more evidence is needed for the safe and active use of SII, NLR and PLR as markers of colorectal cancers.